Topics

Despite another delay, Intercept says its NASH drug remains on track

07:55 EDT 26 Mar 2020 | BioPharmaDive

The coronavirus outbreak, though, adds more uncertainty to what will be a closely watched regulatory review of Intercept's therapy.

Original Article: Despite another delay, Intercept says its NASH drug remains on track

NEXT ARTICLE

More From BioPortfolio on "Despite another delay, Intercept says its NASH drug remains on track"

Quick Search